2023 Annual General Meeting
Fulfilling the Promise of Collaborative Advocacy Leadership: Research Canada’s 18th Annual General Meeting
Tuesday, June 6, 2023 and Wednesday, June 7, 2023
Fairmont Château Laurier
DAY 1: Tuesday, June 6, 2023
4:00 pm – 6:00 pm: Farewell Reception for Research Canada’s President and CEO
DAY 2: Wednesday, June 7, 2023
- 10:00 am – 10:30 am: Refreshments and Networking Opportunity
(Research Canada’s Members, Supporters, and Partners)
- 10:30 am – 12:00 pm: Panel Presentation – Challenges and Innovative Approaches to Antimicrobial Resistance and Future Pandemics
(Research Canada’s Members, Supporters, and Partners)
|Dr. Rose Goldstein, MD
Research Canada Chair
Professor of Medicine, McGill University
|Dr. Rosie Goldstein is a professor in the Faculty of Medicine and the former Vice-Principal of Research and Innovation at McGill University from 2010 to 2017. In 2017, Dr. Goldstein completed the Directors Education Program (DEP) from the Institute of Corporate Directors (ICD). Dr. Goldstein earned her Bachelor of Science and Medical degrees from McGill and completed her clinical training at the Universities of Toronto, Ottawa, and Texas. Dr. Goldstein became Chair of Research Canada in June 2020.
|Dr. Peter Daley, MD, MSc, FRCPC, DTM+H
Associate Professor, Disciplines of Medicine and Laboratory Medicine
Memorial University and Eastern Health
|Dr. Peter Daley’s is an Associate Professor of Medicine in Infectious Diseases at Memorial University in St. John’s. He is the co-chair of the Newfoundland and Labrador Antimicrobial Stewardship Committee and member of the AMMI-Canada Antimicrobial Resistance Steering Group. Peter has published on antimicrobial use surveillance, antimicrobial resistance, the impact of antimicrobial stewardship interventions, and appropriate use of antimicrobials. He has contributed to the National Action Plan on Antimicrobial Resistance and enrolled patients into clinical trials of antimicrobials.
|Dr. Jenine Leal, PhD
Assistant Professor, Community Health Sciences and Microbiology, Immunology and Infectious Diseases and Research Scientist
University of Calgary and Alberta Health Services
|Dr. Jenine Leal is an Assistant Professor at the University of Calgary and an embedded researcher in Infection Prevention and Control at Alberta Health Services. Her research aims to determine the economic burden of AMR to the healthcare system and society and to identify best practices of screening for AMR in hospitalized patients. She conducts population-based, epidemiological, economic, and validation studies using large surveillance and administrative datasets related to AMR.
|Dr. Samira Mubareka, MD
Sunnybrook Health Sciences Centre
|Dr. Samira Mubareka completed her MD at Dalhousie University and Internal Medicine training at McGill University in Canada. She specialized in Infectious Diseases and Medical Microbiology at the University of Manitoba and went on to a research fellowship at the Mount Sinai School of Medicine, New York City. Samira is currently a virologist, medical microbiologist and infectious disease physician at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada and in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. Samira has been working on SARS-CoV-2 since the outset of the pandemic in North America.
|Dr. Brian Ward, MSc, MDCM
Professor, Department of Infectious Diseases & Microbiology, Division of Experimental Medicine
GlycoNet, Research Institute of the McGill University Health Centre (MUHC)
|Dr. Brian Ward’s is a clinician-scientist whose research interests focus on vaccine development for unmet needs and pandemics. Since 2017, he has divided his time between McGill and Medicago, a Quebec-based biotech that licensed the world’s first plant-made vaccine for SARS-COV-2 in 2022. One of his university-based projects is development of a vaccine for Haemophilus influenzae type-a, an orphan disease that causes devastating meningitis in indigenous children. To date, Dr Ward has published >290 peer-reviewed manuscripts.
- 12:10 – 1:30 pm: Parliamentary Health Research Caucus Luncheon – Game-Changing Research and Innovation in Antimicrobial Resistance (AMR) and Emerging Pandemic Threats
Hosted by Dr. Brendan Hanley, MP (Yukon), Chair of the Parliamentary Health Research Caucus, Co-hosted by Vice-Chairs, Dr. Stephen Ellis, MP (Cumberland—Colchester), Ms. Carol Hughes, MP (Algoma—Manitoulin—Kapuskasing) and Senate Representative, The Honourable Mohamed-Iqbal Ravalia (Newfoundland and Labrador)
(Research Canada Members, Supporters and Partners and Parliamentarians – By Invitation Only)
Dr. Amy Lee, PhD, MSc
Dr. Amy Lee is an Early Career Researcher applying innovative genomics and machine learning approaches to develop molecular diagnostics for neonatal sepsis, with the goal of reducing inappropriate antibiotic use. She currently leads several Tri-Council funded projects to understand how AMR pathogens cause diseases in infants both within the Canadian and global contexts (e.g., Malawi, Uganda, and Gambia).
|Dr. Beate Sander, RN, MBA, MEcDev, PhD
Senior Scientist and Professor
University Health Network
|Dr. Beate Sander holds a Canada Research Chair in Economics of Infectious Diseases. She is also a Senior Scientist with the Toronto General Hospital Research Institute at UHN and a Professor at the University of Toronto. Supported by Canadian funding agencies, Dr. Sander’s team uses simulation modeling and real-world data to assess the value of infectious disease interventions, informing public policies for pandemic preparedness, response and recovery. She co-chaired Ontario’s COVID-19 Modelling Consensus Table, helping to shape Ontario’s pandemic response.
|Dr. Fiona Smaill, MB, ChB
Professor Emerita, Department of Pathology and Molecular Medicine,
|Dr. Fiona Smaill is a Professor Emerita in the Department of Pathology and Molecular Medicine at McMaster University. Following a successful career as an academic infectious diseases physician and microbiologist, her interest now is supporting clinical trials of mucosal vaccines for infectious diseases. McMaster’s research on the development of new vaccines for tuberculosis delivered by aerosol positioned the team well to respond to the COVID pandemic and Dr Smaill is presently leading McMaster’s Phase 1 and 2 studies of a novel inhaled COVID vaccine.
- 1:30 pm – 3:00 pm: Research Canada’s 18th Annual General Meeting – Launch of Vision 2025: Fulfilling the Promise of Collaborative Advocacy
(Research Canada Members only)
THANK YOU TO OUR SPONSORS
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system.
GlaxoSmithKline (GSK) is a fully focused biopharma company. GSK prioritizes innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is their R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and their world-leading capabilities in vaccines and medicines development. GSK focuses on four therapeutic areas: infectious diseases, HIV, immunology/respiratory, and oncology.